Tamoxifen citrate - CAS 54965-24-1
Category:
APIs
Product Name:
Tamoxifen citrate
Catalog Number:
54965-24-1
CAS Number:
54965-24-1
Molecular Weight:
563.64
Molecular Formula:
C26H29NO·C6H8O7
COA:
Inquire
MSDS:
Inquire
Chemical Structure
CAS 54965-24-1 Tamoxifen citrate

Reference Reading


1. Two cases with pachydermoperiostosis and discussion of tamoxifen citrate treatment for arthralgia
Aysenur Okten, Ilke Mungan, Mukaddes Kalyoncu, Zerrin Orbak. Clin Rheumatol (2007) 26: 8–11
In this report we discuss the treatment of arthralgia in a patient with PDP. We used tamoxifen citrate and this treatment was successful. In the literature only one re-port presented treatment of arthralgia with tamoxifen citrate in a patient with PDP. In an adolescent with arthralgia, clubbing, and acro-megalic appearance, the physician may have nothing to do for the reversal of clubbing, but does have something to stop the pain. Tamoxifen citrate can be the drug of choice for patients with PDP.
2. Preparation of cross-linked guar gum nanospheres containing tamoxifen citrate by single step emulsion in situ polymer cross-linking method
Jayanta K Sarmah, Saibal Kanti Bhattacharjee. J Incl Phenom Macrocycl Chem (2009) 65:329–334
FTIR experiments were carried out to determine for any drug—polymer interaction in the prepared nanoparticles. Figure 4a, b, c exhibited the FTIR spectra of Pure Tamoxifen Citrate, Guar gum and tamoxifen citrate loaded guar gum nanoparticles. When IR spectra of tamoxifen citrate in nanoparticles was compared with that of powder tamoxifen citrate, a clear loss of resolution of tamoxifen citrate is seen. Further disappearance of the peak at 1,729.8 cm-1 in tamoxifen citrate due to C=O stretching vibration was observed in the drug loaded nanoparticles. Peak at 2,960 cm-1 due to C–H stretching vibration of guargum has been shifted to 2,920 cm-1 in the nanopar-ticles due to presence of tamoxifen citrate. Disappearance of typical bands of tamoxifen citrate such as tertiary amine bands at 900–1,100 cm-1 is also seen in the nanoparticles.
3. Oral tamoxifen citrate treatment is more effective in normogonadotropic patients who have follicle-stimulating hormone levels within the lower half of normal
Teoman Cem Kadioglu. Int Urol Nephrol (2009) 41:773–776
Tamoxifen citrate is a pure anti-estrogen that is a nonsteroidal derivative of triphenyl ethylene. Tamoxifen citrate inhibits hypothalamic estrogen receptors; thus, gonadotropin-releasing hormone (GnRH) secretion is stimulated. As a result of this stimulation, gonadotropin levels increase and stimulate Leydig cells, which enhance production of 5 alfa-dihydrotestosterone in the seminiferous tubules and epididymis. It is assumed that TC affects the testis by blocking the estrogenic receptors of the Leydig cells and increasing testos-terone production by increasing the sensitivity to serum LH.
4. Molecular and Biochemical Aspects of the Neuroprotective Effect of the Selective Estrogen Receptor Modulator Tamoxifen in a Model of Acute Cerebral Ischemia
S. V. Pavlov and I. F. Belenichev. Neurochemical Journal, 2014, Vol. 8, No. 1, pp. 28–32.
To reveal the mechanism of the neuroprotective action of tamoxifen citrate, we also studied its effect on the cellprotection system formed by Hsp70 proteins, whose pronounced deficit we found in animals with ACI. In addition, a number of researchers have hypothesized about Hspmediated effects of selective estrogen receptor modulators. The investigations we performed established that the administration of tamoxifen citrate to the animals with ACI resulted in a significant increase in the con centration of Hsp70 protein in the brain tissue. Note that when we applied the drug the content of Hsp70 protein remained increased, even on the 4th day of the experiment, in contrast to animals from the control group. Densitometric analysis showed an increase in the area and optical density of the Hsppositive complex by 51% as compared to the control group on the same day of ACI (Table 2).